CN116751703A - 用作有结核感染风险的患者的预防剂或用作治疗结核感染患者的辅助剂的组合物 - Google Patents

用作有结核感染风险的患者的预防剂或用作治疗结核感染患者的辅助剂的组合物 Download PDF

Info

Publication number
CN116751703A
CN116751703A CN202310460630.6A CN202310460630A CN116751703A CN 116751703 A CN116751703 A CN 116751703A CN 202310460630 A CN202310460630 A CN 202310460630A CN 116751703 A CN116751703 A CN 116751703A
Authority
CN
China
Prior art keywords
cfu
composition
mycobacterium tuberculosis
tuberculosis
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310460630.6A
Other languages
English (en)
Chinese (zh)
Inventor
卡洛斯·马丁·蒙塔涅斯
胡安·伊格纳西奥·阿奎洛·安尼托
赫苏斯·安吉尔·贡萨洛·阿森西奥
德西斯拉瓦·瓦内娃·马里诺娃
圣地亚哥·尤干达·麦兹
伊斯特本·罗德里格斯·桑切斯
尤金尼亚·普恩特斯·科罗拉多
康塞普西翁·费尔南德斯·阿尔瓦雷斯-桑塔拉诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biological Fabry Co
Universidad de Zaragoza
Original Assignee
Biological Fabry Co
Universidad de Zaragoza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biological Fabry Co, Universidad de Zaragoza filed Critical Biological Fabry Co
Publication of CN116751703A publication Critical patent/CN116751703A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/16—Magnesium; Mg chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/35—Polyols, e.g. glycerin, inositol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202310460630.6A 2018-02-19 2019-02-19 用作有结核感染风险的患者的预防剂或用作治疗结核感染患者的辅助剂的组合物 Pending CN116751703A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18382097 2018-02-19
EP18382097.6 2018-02-19
PCT/EP2019/054106 WO2019158779A1 (en) 2018-02-19 2019-02-19 Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients
CN201980026910.8A CN112449604B (zh) 2018-02-19 2019-02-19 用作有结核感染风险的患者的预防剂或用作治疗结核感染患者的辅助剂的组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980026910.8A Division CN112449604B (zh) 2018-02-19 2019-02-19 用作有结核感染风险的患者的预防剂或用作治疗结核感染患者的辅助剂的组合物

Publications (1)

Publication Number Publication Date
CN116751703A true CN116751703A (zh) 2023-09-15

Family

ID=61557215

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310460630.6A Pending CN116751703A (zh) 2018-02-19 2019-02-19 用作有结核感染风险的患者的预防剂或用作治疗结核感染患者的辅助剂的组合物
CN201980026910.8A Active CN112449604B (zh) 2018-02-19 2019-02-19 用作有结核感染风险的患者的预防剂或用作治疗结核感染患者的辅助剂的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980026910.8A Active CN112449604B (zh) 2018-02-19 2019-02-19 用作有结核感染风险的患者的预防剂或用作治疗结核感染患者的辅助剂的组合物

Country Status (9)

Country Link
US (3) US11826411B2 (https=)
EP (2) EP3755374B1 (https=)
JP (3) JP7388636B2 (https=)
CN (2) CN116751703A (https=)
AU (2) AU2019221709B2 (https=)
BR (1) BR112020016704A2 (https=)
CA (1) CA3091304A1 (https=)
ES (1) ES2967066T3 (https=)
WO (1) WO2019158779A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3797791A1 (en) * 2019-09-26 2021-03-31 Universidad De Zaragoza Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria
CN113122484B (zh) * 2021-06-03 2023-11-03 郑州安图生物工程股份有限公司 一种非结核分枝杆菌的冻干保护剂及其制备方法和保藏方法
WO2025063217A1 (ja) 2023-09-20 2025-03-27 住友金属鉱山株式会社 赤外線吸収粒子、赤外線吸収粒子分散液、赤外線吸収透明基材、赤外線吸収粒子分散体、赤外線吸収合わせ透明基材

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1108956A (en) * 1964-05-26 1968-04-10 Ciba Ltd Process for the manufacture of bcg vaccines
BR9808441A (pt) * 1997-03-28 2000-05-23 Cytoclonal Pharmaceutics Inc Composição farmacêutica para administração a um animal, vetor transportador, vetores para transportar e expressar genes selecionados em escherichia coli e de uma cepa de mycobacterium, processo para administrar a um animal uma quantidade eficaz da composição farmacêutica, e, meio de cultura.
BRPI0709106B8 (pt) * 2006-03-24 2021-05-25 Univ Zaragoza vacina contra tuberculose
CN104324365B (zh) * 2014-10-24 2016-03-16 孙二琳 重组人干扰素-α-2b-BCG的干粉剂制备方法
ES2615512B1 (es) 2015-11-06 2018-03-15 Universidad De Zaragoza Dispositivo y sistema microfluídico para el estudio de cultivos celulares
ES2626237B1 (es) 2015-12-22 2018-05-03 Universidad De Zaragoza Sistema electrónico de potencia modular variable para la generación de pulsos eléctricos y usos asociados
WO2018006939A1 (en) 2016-07-05 2018-01-11 Universidad De Zaragoza Inactivated tuberculosis vaccine
ES2679721B1 (es) 2017-01-18 2019-06-21 Univ Zaragoza Generador de aerosoles nanoparticulados y procedimiento de generacion de aerosoles en continuo asociado a dicho generador
ES2738926A1 (es) 2018-07-26 2020-01-27 Univ Zaragoza Granulisina, metodo de obtencion y usos

Also Published As

Publication number Publication date
CA3091304A1 (en) 2019-08-22
AU2019221709B2 (en) 2024-04-18
JP2021514392A (ja) 2021-06-10
EP3755374B1 (en) 2023-11-15
EP4233912A3 (en) 2023-11-01
US20240382575A1 (en) 2024-11-21
WO2019158779A1 (en) 2019-08-22
AU2019221709A1 (en) 2020-10-15
US20230165948A1 (en) 2023-06-01
CN112449604B (zh) 2023-05-26
AU2024203034A1 (en) 2024-05-30
EP4233912A2 (en) 2023-08-30
JP7388636B2 (ja) 2023-11-29
EP3755374A1 (en) 2020-12-30
ES2967066T3 (es) 2024-04-25
EP3755374C0 (en) 2023-11-15
RU2020130786A (ru) 2022-03-21
CN112449604A (zh) 2021-03-05
BR112020016704A2 (pt) 2020-12-15
US11826411B2 (en) 2023-11-28
JP2025160294A (ja) 2025-10-22
JP2023153868A (ja) 2023-10-18
US20230330201A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
US20230330201A1 (en) Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients
US7829104B2 (en) Electroporation of Mycobacterium and overexpression of antigens in mycobacteria
KR101329323B1 (ko) 엔도솜을 이탈하는 능력이 보강된 재조합 비씨지 균주
JP5461776B2 (ja) マイコバクテリウムのエレクトロポレーションおよびマイコバクテリア中における抗原類の過剰発現
Lopez et al. Safety and immunogenicity of a live-attenuated auxotrophic candidate vaccine against the intracellular pathogen Rhodococcus equi
US20130022638A1 (en) Tuberculosis Vaccine
JP6229080B2 (ja) 新規な温度敏感性マイコバクテリア菌株を含むマイコバクテリア感染症に対するワクチン組成物
EP2161035B1 (en) Bordetella parapertussis-containing whole-cell vaccine composition
RU2778094C2 (ru) Композиции для применения в качестве профилактического средства для пациентов с риском туберкулезной инфекции или в качестве вторичных средств для лечения пациентов с туберкулезной инфекцией
JP4705573B2 (ja) 弱毒細菌生ワクチン
CN114845732B (zh) 通过肺部递送减毒活分枝杆菌的治疗效果
Rahimi et al. A Global Overview of Tuberculosis Vaccine Development

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination